Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

PURPOSE: Tislelizumab is an anti–programmed cell death protein 1 (anti–PD-1) monoclonal antibody specifically designed to minimize binding to Fcγ receptors (FcγR). PATIENTS AND METHODS: Here, we present the extended 3-year follow-up of a phase II study of tislelizumab in 70 patients with relapsed/re...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuqin, Gao, Quanli, Zhang, Huilai, Fan, Lei, Zhou, Jianfeng, Zou, Dehui, Li, Wei, Yang, Haiyan, Liu, Ting, Wang, Quanshun, Lv, Fangfang, Guo, Haiyi, Zhao, Xia, Wang, Dan, Zhang, Pei, Wang, Yidi, Wang, Lei, Liu, Tengfei, Zhang, Yun, Shen, Zhirong, Huang, Jane, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365351/
https://www.ncbi.nlm.nih.gov/pubmed/34716199
http://dx.doi.org/10.1158/1078-0432.CCR-21-2023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365351/
https://www.ncbi.nlm.nih.gov/pubmed/34716199
http://dx.doi.org/10.1158/1078-0432.CCR-21-2023

Ejemplares similares